Center for Childhood Cancer Research
CCCR Newsletter
Facebook
Twitter
Ways to Give
Search...
Home
About
Colket Translational Research Building
Abramson Cancer Center
Research Programs & Laboratories
Ways To Give
Donate Now
Research
Hematopoietic Malignancies
Brain Tumors
Neuroblastoma
Sarcoma
Survivorship
Behavioral Oncology
Developmental Therapeutics
Our Team
Leadership
Faculty
Research Administration
Training
Biomedical Graduate Groups
Clinical Fellowships
Cancer Center T32
Cancer Center K12
Clinical Trials
Protocol Search
News & Events
CCCR Newsletter
View Funding Opportunities
CCCR Publications from July 1st 2010 to June 30th 2011
CCCR-ALSF Symposium on Translational Oncology
Contact Us
Faculty
Research Administration
Skip to content
Home
Research
Neuroblastoma
Peter C. Adamson, MD
Peter C. Adamson, MD
Neuroblastoma and Other Embryonal Tumors
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.
Journal of Clinical Oncology. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Nature. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci.
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.
Research Neuroblastoma Peter C. Adamson, MD